Zydus Lifesciences gains FDA tentative approval for generic ibrutinib, enhancing access to vital cancer treatment for ...

Rituximab used off label appears tolerable and effective in a variety of autoimmune diseases. ... You are encouraged to report adverse drug event information to the FDA.

The FDA has decided not to approve glofitamab plus gemcitabine and oxaliplatin to treat certain patients with relapsed/refractory DLBCL.

Celgene Corporation (($CELG)) announced an update on their ongoing clinical study. Celgene Corporation recently completed a Phase 3B study titled ...

The primary outcome of time to next treatment (TTNT) was not yet reached (95% CI 15.6-not estimable) in the maintenance group, 14.8 years (95% CI 7.5-not reached) in the induction group, and 5.6 ...

The FDA determined the data from STARGLO did not provide sufficient evidence to support approving glofitamab-gxbm (Columvi) in combination with gemcitabine and oxaliplatin to treat relapsed/refractory ...

The study involved 89 pediatric patients, aged 12-15 years, who received combination rituximab and cyclophosphamide therapy for a rheumatic disease at a single center between January 2020 and ...

Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor–Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic ...

Glofitamab is a bispecific CD20-directed CD3 T-cell engager approved under the brand name Columvi ® for the treatment of adults with R/R DLBCL, not otherwise specified or large B-cell lymphoma arising ...